ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Iovance Biotherapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the July 14, 2025 deadline [2]. Group 2: Allegations Against Iovance - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of new Authorized Treatment Centers (ATCs) in treating patients with Amtagvi, leading to longer timelines and higher patient drop-offs [3]. - It is claimed that these issues resulted in increased costs and lower revenue for Iovance, as ATCs could not keep pace with the manufactured product, contradicting the company's positive statements about its business and prospects [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including securing over $438 million for investors in 2019 alone [4].